CA3038528A1 - Compositions and methods for treating ophthalmic conditions - Google Patents
Compositions and methods for treating ophthalmic conditions Download PDFInfo
- Publication number
- CA3038528A1 CA3038528A1 CA3038528A CA3038528A CA3038528A1 CA 3038528 A1 CA3038528 A1 CA 3038528A1 CA 3038528 A CA3038528 A CA 3038528A CA 3038528 A CA3038528 A CA 3038528A CA 3038528 A1 CA3038528 A1 CA 3038528A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- composition
- pharmaceutically acceptable
- formula
- ophthalmic condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400955P | 2016-09-28 | 2016-09-28 | |
| US62/400,955 | 2016-09-28 | ||
| US201762564595P | 2017-09-28 | 2017-09-28 | |
| PCT/US2017/054051 WO2018064354A1 (en) | 2016-09-28 | 2017-09-28 | Compositions and methods for treating ophthalmic conditions |
| US62/564,595 | 2017-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3038528A1 true CA3038528A1 (en) | 2018-04-05 |
Family
ID=61760847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3038528A Pending CA3038528A1 (en) | 2016-09-28 | 2017-09-28 | Compositions and methods for treating ophthalmic conditions |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11510931B2 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7030345B2 (cg-RX-API-DMAC10.html) |
| AU (2) | AU2017336765B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112019006160A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3038528A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2019003623A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018064354A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| CN108135737B (zh) | 2015-06-06 | 2021-11-05 | 拨云生物医药科技(广州)有限公司 | 用于治疗翼状胬肉的组合物和方法 |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| CN109152774A (zh) | 2016-05-09 | 2019-01-04 | 奥尔德拉医疗公司 | 眼部炎性病症和疾病的组合治疗 |
| BR112018074450A2 (pt) | 2016-06-02 | 2019-03-19 | Cloudbreak Therapeutics, Llc | composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma |
| WO2018064354A1 (en) | 2016-09-28 | 2018-04-05 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| CA3077033A1 (en) * | 2017-09-28 | 2019-04-04 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| WO2020018498A1 (en) * | 2018-07-16 | 2020-01-23 | Aldeyra Therapeutics, Inc. | Cyclodextrin formulations |
| CN112714762A (zh) | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| WO2020047197A1 (en) * | 2018-08-29 | 2020-03-05 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| CN113056353B (zh) | 2018-09-25 | 2022-11-01 | 奥尔德拉医疗公司 | 用于治疗干眼病的调配物 |
| ES2990204T3 (es) * | 2018-10-19 | 2024-11-29 | Univ Minnesota | Procedimientos de aislamiento y utilización de la membrana de Descemet y composiciones que incluyen membrana de Descemet aislada |
| KR102151051B1 (ko) * | 2019-01-10 | 2020-09-02 | 고려대학교 산학협력단 | 당뇨병성 백내장 치료 또는 예방용 조성물 |
| US11786518B2 (en) | 2019-03-26 | 2023-10-17 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| CN113784954A (zh) | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| BR112021026662A2 (pt) * | 2019-09-10 | 2022-04-12 | Cloudbreak Therapeutics Llc | Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2022031830A1 (en) * | 2020-08-04 | 2022-02-10 | Harrow Ip Llc | Antibacterial compositions and methods for fabricating thereof |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| EP4288151A4 (en) | 2021-02-03 | 2025-01-01 | ADS Therapeutics LLC | Topical ophthalmological compositions |
| US11213551B1 (en) | 2021-04-05 | 2022-01-04 | Korb Research, Llc. | Ocular treatment compositions and methods of use thereof |
| RS64402B1 (sr) * | 2021-05-24 | 2023-08-31 | Medicon Pharmaceuticals Inc | Lečenje bola povezanog sa dijabetičkom perifernom neuropatijom |
| PL4114403T3 (pl) | 2021-05-24 | 2023-10-09 | Medicon Pharmaceuticals, Inc. | Leczenie bólu neuropatycznego towarzyszącego neuropatii obwodowej indukowanej przez chemioterapię |
| AU2023273823A1 (en) * | 2022-05-18 | 2024-12-05 | Glaukos Corporation | Novel applications of zwitterions in ophthalmic topical cream compositions and preparations |
| WO2025111079A1 (en) | 2023-11-21 | 2025-05-30 | Medicon Pharmaceuticals, Inc. | Isomers of phosphosulindac |
| WO2025176750A1 (en) | 2024-02-23 | 2025-08-28 | Heinrich-Heine-Universität Düsseldorf | Dual targeting in a new class of active ingredients |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US4309566A (en) | 1979-11-05 | 1982-01-05 | Fmc Corporation | Plant regulator |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| AU684950B2 (en) | 1994-05-06 | 1998-01-08 | Alcon Laboratories, Inc. | Use of vitamin E tocopheryl derivatives in ophthalmic compositions |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| RU26988U1 (ru) | 2002-05-06 | 2003-01-10 | Закрытое акционерное общество "ДУКС-ЛИЗИНГ" | Кондуктор для сверления отверстий |
| US20080153746A1 (en) | 2004-04-06 | 2008-06-26 | Transmolecular, Inc. | Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers |
| CN1976692B (zh) | 2004-06-23 | 2011-05-25 | 矫正诊疗公司 | 用视黄基衍生物治疗眼部疾病的方法和组合物 |
| US20070299124A1 (en) | 2006-01-25 | 2007-12-27 | Ousler George W Iii | Formulations and methods for treating dry eye |
| CN101754748A (zh) | 2007-05-24 | 2010-06-23 | 阿西克斯医疗公司 | 治疗干眼症的制剂和方法 |
| WO2009023631A1 (en) | 2007-08-10 | 2009-02-19 | Basil Rigas | Anti-inflammatory compounds and uses thereof |
| US20120295979A1 (en) | 2011-05-03 | 2012-11-22 | Florida Atlantic University | Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress |
| WO2013130625A1 (en) * | 2012-02-27 | 2013-09-06 | Basil Rigas | Phospho-ester derivatives and uses thereof |
| CA2885740A1 (en) | 2012-09-21 | 2014-03-27 | Basil Rigas | Compounds and compositions for use in the prevention and treatment of inflammation-related disorders, pain and fever, skin disorders, cancer and precancerous conditions thereof |
| US20160051526A1 (en) | 2013-04-09 | 2016-02-25 | Cresset Biomolecular Discovery Ltd | The Local Treatment of Inflammatory Ophthalmic Disorders |
| WO2018064354A1 (en) | 2016-09-28 | 2018-04-05 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| CA3077033A1 (en) | 2017-09-28 | 2019-04-04 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
-
2017
- 2017-09-28 WO PCT/US2017/054051 patent/WO2018064354A1/en not_active Ceased
- 2017-09-28 CA CA3038528A patent/CA3038528A1/en active Pending
- 2017-09-28 BR BR112019006160A patent/BR112019006160A2/pt not_active Application Discontinuation
- 2017-09-28 MX MX2019003623A patent/MX2019003623A/es unknown
- 2017-09-28 JP JP2019538106A patent/JP7030345B2/ja active Active
- 2017-09-28 AU AU2017336765A patent/AU2017336765B2/en active Active
- 2017-09-28 US US16/337,734 patent/US11510931B2/en active Active
-
2022
- 2022-11-08 US US18/053,503 patent/US20230293557A1/en not_active Abandoned
-
2023
- 2023-09-07 AU AU2023226711A patent/AU2023226711A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017336765A1 (en) | 2019-04-18 |
| US11510931B2 (en) | 2022-11-29 |
| AU2023226711A1 (en) | 2023-09-21 |
| BR112019006160A2 (pt) | 2019-06-18 |
| US20230293557A1 (en) | 2023-09-21 |
| MX2019003623A (es) | 2019-09-23 |
| WO2018064354A1 (en) | 2018-04-05 |
| US20190343848A1 (en) | 2019-11-14 |
| JP2019533016A (ja) | 2019-11-14 |
| AU2017336765B2 (en) | 2023-06-08 |
| JP7030345B2 (ja) | 2022-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230293557A1 (en) | Compositions and methods for treating ophthalmic conditions | |
| US20220233556A1 (en) | Compositions and methods for treating ophthalmic conditions | |
| JP5421272B2 (ja) | 眼病治療のための組成物及び方法 | |
| JP7116490B2 (ja) | 眼の炎症性障害および疾患の組合せ処置 | |
| CN103037691A (zh) | 用于预防和治疗高眼压症和青光眼的方法和药物 | |
| US20130253019A1 (en) | Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye | |
| EP3519050B1 (en) | Compositions for treating ophthalmic conditions | |
| EP4167965A1 (en) | Use of high molecular weight hyaluronic acid as ocular transporting vehicle | |
| ES2984281T3 (es) | Composiciones que comprenden un antagonista de la aldosterona para su uso en el tratamiento de ojos secos | |
| HK40012460A (en) | Compositions for treating ophthalmic conditions | |
| HK40012460B (en) | Compositions for treating ophthalmic conditions | |
| HK40014113A (zh) | 用於治疗眼科病况的组合物和方法 | |
| AU2014201375B2 (en) | Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions | |
| Schmitt | Design and development of ocular formulations for preclinical and clinical trials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220824 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - SMALL Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240906 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240906 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240906 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - SMALL Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250729 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250730 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251111 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260114 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260114 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - SMALL Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260804 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260804 |